Glaxosmithkline Share News (GSK)

GlaxoSmithKline says CEO Witty to retire next year

LONDON, March 17 (Reuters) - GlaxoSmithKline said its Chief Executive Andrew Witty would retire in 2017 having held the position since 2008, prompting the British pharmaceutical company to start looking for his successor. Witty, a 31-year company veteran, has been under fire from some inves

GlaxoSmithKline Chief Andrew Witty To Retire In March 2017

GlaxoSmithKline's Witty to retire in early 2017

(ShareCast News) - Bowing to pressure from institutional shareholders, GlaxoSmithKline chief executive Andrew Witty has decided to retire from the company at the end of March next year. The FTSE 100 drug maker will now conduct a formal search for a successor, though reports have indicated it has bee

UPDATE 1-Vectura to buy SkyePharma for $620 mln as UK biotech consolidates

* Agreed offer values SkyePharma at 410.15 pence a share * Combined group market value more than 1 billion pounds (Adds more on rationale for deal, comment from CEO) By Ben Hirschler LONDON, March 16 (Reuters) - Respiratory drug specialist Vectura has agreed to buy rival SkyeP

GlaxoSmithKline Signs Cell Therapy Agreement With Miltenyi Biotec

Bristol-Myers Squibb says stops some initiatives in China

LONDON, March 8 (Reuters) - U.S. drugmaker Bristol-Myers Squibb said on Tuesday it had stopped "certain initiatives" in China, when asked by Reuters to comment on industry chatter it was curbing financial incentives for prescribing doctors. Payments to healthcare professionals in China are

GSK reveals "significant improvement" in Nucala severe asthma tests

(ShareCast News) - GlaxoSmithKline has reported encouraging data on the effect of its Nucala drug on severe asthma sufferers. GSK presented results at the American Academy of Allergy, Asthma & Immunology (AAAAI) late on Monday that showed patients with severe asthma experienced a "significant improv

WINNERS & LOSERS SUMMARY: Break Up Speculation Lifts Old Mutual

UPDATE: GlaxoSmithKline Advair Diskus, Nucala Study Results Presented

Glaxo's Advair Diskus study results published by NEJM

(ShareCast News) - Results from GlaxoSmithKline's long-term safety study of Advair Diskus for the treatment of adults and adolescents with asthma have been published by the New England Journal of Medicine. Kate Knobil, chief medical officer of pharmaceuticals at GSK said: "We are pleased that this s

GlaxoSmithKline Advair Diskus Study Results Published And Presented

London pre-open: Stocks seen lower on profit-taking

(ShareCast News) - London stocks are expected to open a little weaker on Monday as investors look to book some profits following recent gains. The FTSE 100 is seen starting 29 points lower than Friday's close at 6,170. Michael Hewson, chief market analyst at CMC Markets, said: "Despite this recover

GlaxoSmithKline: Low Rate Of Organ Damage Progression For Benlysta

Swiss Basilea says profits still 2-3 years away

* CFO expects profitability in 2-3 years * Basilea hopes new anti-infection drugs mitigate setbacks * GSK dumped U.S. approval bid for Basilea skin drug in January By John Miller and Paul Arnold ZURICH, Feb 29 (Reuters) - Swiss drugmaker Basilea expects to move into profi

GlaxoSmithKline starts hunt for successor to CEO Witty

* Drugmaker's chairman sees succession planning as priority * New CEO not expected to take over before 2017 By Ben Hirschler LONDON, Feb 29 (Reuters) - GlaxoSmithKline's chairman is starting the process of seeking a new chief executive to succeed Andrew Witty, although a handov